Skip to main content

CCTG Connection



Published:
Category: Group updates

The Allan Blair Cancer Centre IND234 trial team has been awarded the 2022 CCTG IND Team Award for performance in trial accrual, local activation timelines, and compliance metrics, team performance.

Read More

Published:
Category: Group updates

Dr. Jonathan Loree has been recognized for his Phase III research contributions with the CCTG 2022 Dr. Ralph Meyer Phase III Young Investigator Award.

Read More

Published:
Category: Group updates

CCTG congratulates BC Cancer Vancouver GCC1 Trial Team whose work was recognized with the 2022 CCTG Phase III Team Award, for performance in trial accrual, local activation timelines, compliance metrics and team performance.

Read More

Published:
Category: Trials
New group publications now online. Read More



Published:
Category: Group updates
CCTG is looking for two new Patient Representatives

CCTG is currently seeking volunteer Patient Representatives for the Brain Disease Site Committee (brain cancer) as well as for the Head and Neck Disease Site Committee (cancer inside the nose, throat or mouth). Patient Representatives participate in all aspects of disease site committee activities and are members of the CCTG Patient Representative Committee.

Read More

Published:
Category: News
The ability to move cancer research findings into practice, for the benefit of those affected by cancer, is the goal driving most research questions. CCS is not only a cancer research funder, but also plays critical information, support and advocacy roles within the Canadian cancer ecosystem, with the goal of saving and improving the lives of people affected by cancer. With the recent launch of the Centre for Cancer Prevention and Support (CCPS), our ability to coalesce research results with our mission work to drive impact more effectively is enhanced. The Canadian Cancer Society’s (CCS) forthcoming research strategy aims to put people at its core and deliver results that will significantly improve the outlook for people affected by cancer in Canada by 2040. To achieve this, we are committed to investing in research that will drive accelerated progress beyond academia, identifying and filling the critical gaps that exist, and applying current knowledge about what we know works. Read More

Published:
Category: Trials
Trial Activation: MCY2
The CCTG MYC2 study: Phase III Study of SC Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study S1803)” has been centrally activated.
 
Daratumumab is an anti CD38 monoclonal antibody which is commonly used to treat multiple myeloma.
Read More

Published:
Category: Trials
Trial closures. IND236 : "A Phase Ib and Open Label Phase II Study of CFI-402257 in Combination with Weekly Paclitaxel in Patients with Advanced/Metastatic HER2-Negative Breast Cancer was closed to accrual after reaching its Stage I accrual target." BR36 : "A Biomarker-Directed, Open Label, Multi-Centre Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients with Non-Small Cell Lung Cancer" Read More